In which adults with coronary heart disease is the Roma Pharmaceuticals Limited Ezetimibe/Atorvastatin product indicated to reduce cardiovascular events?

The Roma Pharmaceuticals Limited Ezetimibe/Atorvastatin product is indicated as substitution therapy to reduce cardiovascular events in adults with coronary heart disease and a history of acute coronary syndrome who are adequately controlled on concurrent separate atorvastatin and ezetimibe at the same doses as the fixed combination.